These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19932151)

  • 1. Regulation of prostate cancer cell proliferation by somatostatin receptor activation.
    Ruscica M; Arvigo M; Gatto F; Dozio E; Feltrin D; Culler MD; Minuto F; Motta M; Ferone D; Magni P
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):254-62. PubMed ID: 19932151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.
    Ruscica M; Magni P; Steffani L; Gatto F; Albertelli M; Rametta R; Valenti L; Ameri P; Magnaghi V; Culler MD; Minuto F; Ferone D; Arvigo M
    Mol Cell Endocrinol; 2014 Feb; 382(2):860-70. PubMed ID: 24211300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.
    Ferone D; Arvigo M; Semino C; Jaquet P; Saveanu A; Taylor JE; Moreau JP; Culler MD; Albertelli M; Minuto F; Barreca A
    Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E1044-50. PubMed ID: 16046458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog.
    Tatoud R; Degeorges A; Prévost G; Hoepffner JL; Gauvillé C; Millot G; Thomas F; Calvo F
    Mol Cell Endocrinol; 1995 Sep; 113(2):195-204. PubMed ID: 8674827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A functional comparison of recombinant and native somatostatin sst2 receptor variants in epithelia.
    Holliday ND; Tough IR; Cox HM
    Br J Pharmacol; 2007 Sep; 152(1):132-40. PubMed ID: 17603546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
    Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
    Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.
    Arvigo M; Gatto F; Ruscica M; Ameri P; Dozio E; Albertelli M; Culler MD; Motta M; Minuto F; Magni P; Ferone D
    J Endocrinol; 2010 Dec; 207(3):309-17. PubMed ID: 20876239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A; Lavaque E; Gunz G; Barlier A; Kim S; Taylor JE; Culler MD; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2.
    Sharif N; Gendron L; Wowchuk J; Sarret P; Mazella J; Beaudet A; Stroh T
    Endocrinology; 2007 May; 148(5):2095-105. PubMed ID: 17272399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.
    Zatelli MC; Tagliati F; Piccin D; Taylor JE; Culler MD; Bondanelli M; degli Uberti EC
    Biochem Biophys Res Commun; 2002 Oct; 297(4):828-34. PubMed ID: 12359227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists.
    Bocci G; Culler MD; Fioravanti A; Orlandi P; Fasciani A; Colucci R; Taylor JE; Sadat D; Danesi R; Del Tacca M
    Eur J Clin Invest; 2007 Sep; 37(9):700-8. PubMed ID: 17696959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism.
    Wilkinson GF; Feniuk W; Humphrey PP
    Br J Pharmacol; 1997 May; 121(1):91-6. PubMed ID: 9146892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.
    Cervia D; Nunn C; Fehlmann D; Langenegger D; Schuepbach E; Hoyer D
    Br J Pharmacol; 2003 May; 139(1):109-21. PubMed ID: 12746229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules.
    Gruszka A; Ren SG; Dong J; Culler MD; Melmed S
    Endocrinology; 2007 Dec; 148(12):6107-14. PubMed ID: 17656461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone affects gene expression and proliferation in human prostate cancer cells.
    Bidosee M; Karry R; Weiss-Messer E; Barkey RJ
    Int J Androl; 2011 Apr; 34(2):124-37. PubMed ID: 20546049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.